Skip to main content

Flexible Dosing of Rybelsus® vs. Sitagliptin 100 mg (PIONEER 7 Study)

This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Flexible Dosing of Rybelsus® vs. Sitagliptin 100 mg (PIONEER 7 Study)

Chapters
Transcript
References

Return to overview

Transcripts

Return to overview

References